Masimo Corp (MASI) Earnings: 2025 Adjusted EPS Forecast Surpasses Estimates with $4.90-$5.10 Range

Masimo Corp on Smartkarma

Analyst coverage of Masimo Corporation on Smartkarma, a platform for independent investment research, has been positive. Baptista Research, a reputable provider on Smartkarma, has published insightful reports on Masimo Corp. In their report titled “Masimo Corporation: Here Are the 6 Most Critical Factors Shaping Its Performance in 2025 & Beyond! – Major Drivers,” they highlighted the company’s strong performance in the healthcare segment. Masimo reported robust financial results for the third quarter of 2024, with healthcare revenues reaching $343 million, showing a 12% year-over-year growth driven by increased consumable and service revenues.

Furthermore, Baptista Research‘s report on “Masimo Corporation: Expansion into Consumer Health Products & Other Major Drivers” emphasized Masimo’s growth and challenges. The company’s second-quarter earnings revealed a 23% year-on-year growth in healthcare revenues, totaling $344 million, supported by a significant increase in consumables and service revenue. This growth is attributed to strong demand for Masimo sensors, fueled by hospital conversions and the normalization of installations, showcasing a positive trend in Masimo Corp‘s performance and expansion.

A look at Masimo Corp Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking ahead, Masimo Corp seems to have a positive long-term outlook based on the Smartkarma Smart Scores analysis. With a strong momentum score of 5, the company is showing significant positive price trend and investor sentiment. Additionally, Masimo Corp scores well in resilience with a score of 3, indicating a good ability to weather economic downturns and market volatility. Despite lower scores in value and dividend factors, the company’s growth score of 2 suggests potential for expansion and development in the future.

Considering Masimo Corporation’s focus on designing and developing innovative medical technologies for noninvasive physiological monitoring, the company’s overall outlook appears promising. Although the Smart Scores point to some areas for improvement, Masimo Corp‘s emphasis on improving pulse oximetry efficiency reflects its commitment to advancing medical monitoring capabilities. Investors may find value in monitoring Masimo Corp‘s growth trajectory and momentum in the coming years.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma